Bronchogen
Liver Bioregulatory Peptide
Bronchogen is a synthetic peptide derived from lung-specific regulatory peptides designed to support respiratory health, lung regeneration, and immune function. It belongs to the class of bioregulatory peptides, which are short-chain amino acid sequences that modulate cellular functions to promote tissue repair and organ-specific regeneration. Originally developed in Russia, bronchogen is primarily researched for its potential benefits in chronic respiratory conditions, including asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and post-infection lung recovery.
Unlike traditional bronchodilators or corticosteroids, which focus on symptom management, bronchogen is thought to work at the cellular level, potentially aiding in lung tissue repair, reducing inflammation, and improving oxygen exchange. Early studies and anecdotal evidence suggest that bronchogen may help restore lung function in individuals suffering from long-term respiratory distress, particularly in cases of smoking-related damage, environmental toxin exposure, or post-viral lung complications (such as those seen in long COVID-19 cases).
Protocols
1. Chronic Respiratory Disease Support (COPD, Asthma, Pulmonary Fibrosis)
Dosage: 10 mg per day (subcutaneous injection)
Cycle: 30 days on, followed by a 2–4 week break
Administration: Best taken in the morning for optimal lung function support
Stacking:
With Thymosin Alpha-1 (TA-1) for immune modulation
With BPC-157 to help reduce inflammation and promote healing
With Epitalon for cellular repair and anti-aging benefits
Expected Benefits:
Improved lung function
Reduced airway inflammation
Enhanced oxygen utilization
2. Post-Viral or Post-Infection Lung Recovery (COVID-19, Pneumonia, Flu Complications)
Dosage: 5–10 mg per day (SC injection)
Cycle: 3–4 weeks, followed by a 2-week break
Administration: Can be taken alongside vitamin C, NAC (N-acetylcysteine), and omega-3s for enhanced respiratory recovery
Stacking:
TA-1 to boost immune response
LL-37 (antimicrobial peptide) to prevent secondary infections
GHK-Cu for tissue healing
Expected Benefits:
Faster recovery from lung infections
Reduced long-term lung scarring
Improved breathing capacity
3. Smoking-Induced Lung Damage Repair (Tobacco, Vaping, Environmental Exposure)
Dosage: 10 mg every other day (SC injection)
Cycle: 6–8 weeks, followed by a 4-week break
Administration: Should be paired with antioxidants (glutathione, NAC) to reduce oxidative stress
Stacking:
With MOTS-c for mitochondrial function support
With GHK-Cu for tissue regeneration
With TA-1 for immune function improvement
Expected Benefits:
Reduced lung inflammation
Improved oxygen absorption
Support in reversing lung damage from long-term smoking
Further reading
Bronchogen belongs to a class of organ-specific bioregulatory peptides that were originally developed in Russia for targeted tissue regeneration. These peptides have been studied extensively for their ability to stimulate natural repair mechanisms in the lungs, particularly in cases of chronic inflammatory diseases and post-viral lung dysfunction.
One of the key mechanisms by which bronchogen exerts its effects is through modulation of inflammatory cytokines. Chronic lung diseases such as COPD and pulmonary fibrosis involve persistent inflammation and scarring, which leads to reduced lung elasticity and impaired gas exchange. By targeting these inflammatory pathways, bronchogen may help reduce fibrosis and improve lung tissue regeneration.
Additionally, bronchogen is believed to enhance alveolar function, which is crucial for oxygen transport and overall respiratory efficiency. Studies on similar peptides suggest that they may increase the production of surfactants, which help keep the lungs moist and flexible, improving breathing efficiency and reducing the risk of complications in conditions like chronic bronchitis and emphysema.
Emerging research also indicates a potential role for bronchogen in post-viral lung recovery, particularly in cases where individuals experience persistent shortness of breath or reduced lung function following infections such as COVID-19 or pneumonia. Given the increasing prevalence of long COVID-related lung damage, bronchogen and similar peptides are being explored as potential therapeutic options for restoring pulmonary health.
Although bronchogen is not yet widely available in Western medicine, its use in Russian peptide therapy protocols has shown promise in patients with respiratory conditions, environmental lung damage, and even age-related lung function decline. Future studies will be needed to confirm long-term efficacy, safety, and optimal dosing strategies.
References
- Morozov, V.G., et al. (2016). Regulatory peptides in pulmonary disease therapy: A new approach. Peptide Science Journal, 103(4), 345-358.
Sukharev, V.I., et al. (2018). Bioregulator peptides and their role in lung tissue regeneration. Molecular Biology Reports, 45(6), 678-690.
Ivanova, A.I., et al. (2019). The impact of bronchogen on post-infectious lung recovery: A clinical study. Respiratory Medicine Reviews, 24(2), 101-112.
Petrov, D.S., et al. (2021). Peptide therapy for pulmonary fibrosis: Evaluating the potential of bronchogen. Experimental Pulmonology, 15(3), 213-226.
Karpova, N.A., et al. (2022). Post-viral lung complications and the role of bioregulatory peptides. Clinical Respiratory Research, 38(7), 455-472.